Liminatus Pharma, Inc. Class A Common Stock
Here’s whether Liminatus Pharma, Inc. Class A Common Stock (LIMN) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: RSI 61 — healthy momentum range. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-24.98% over 10 days); 3-month momentum negative (-71.5%); rising volume on a downtrend (distribution, 2.53x avg). Currently 99.3% off its 52-week high. Score: -4/7.
LIMN is trading below its 200-day MA ($1.86) — a key warning sign the longer-term trend is under pressure. An RSI of 61.0 sits in the neutral zone — momentum is neither stretched nor exhausted. With ~12 months of trading history, the return since first available bar is -97.8%. The current 99.3% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.